Merck to initiate EXPrESSIVE phase 3 trials of MK-8527, an investigational once-monthly HIV prevention pill
Merck, known as MSD outside of the United States and Canada, announced the initiation of the EXPrESSIVE phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase …